EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Targeting the ST3 beta‐galactoside alpha‐2,3‐sialyltransferase 1 ( ST3Gal1 ) as a potential therapeutic strategy to overcome anti‐ VEGF resistance in endometrial cancer

Chia-Hao Liu iD, Szu-Ting Yang, Wei-Ting Chao, Chen-Hao Lin, Yu-Chieh Lee, Chiung-Ru Lai, Shie-Liang Hsieh iD, Liang-Wei Wang, Peng-Hui Wang iD

International Journal of Gynecology & Obstetrics · 2025-12 · 171 (3) · 1343-1354

DOI: 10.1002/ijgo.70292 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Gynecology & Obstetrics, online erschienen am 11.06.2025. Verfasst von Chia-Hao Liu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Taipei Veterans General Hospital, Taipei, Taiwan. Hauptthemen laut MEDLINE: Sialyltransferases, Endometrial Neoplasms, Vascular Endothelial Growth Factor A. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Science and Technology Council, Taipei Veterans General Hospital, Female Cancer Foundation, Taipei, Taiwan.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To investigate the role of ST3 beta‐galactoside alpha‐2,3‐sialyltransferase 1 (ST3Gal1) in endometrial cancer (EC) progression and its potential as a therapeutic target to enhance the efficacy of antiangiogenic treatment.

Methods

ST3Gal1 expression and its clinical relevance were analyzed in EC tissues. Functional assays evaluated its effects on vascular endothelial growth factor‐A (VEGF‐A) expression, epithelial–mesenchymal transition (EMT), and cell invasiveness. Mechanistic studies, including Duolink proximity ligation assays and co‐immunoprecipitation, examined ST3Gal1–VEGF‐A interactions. ST3Gal1 was inhibited genetically or pharmacologically using soyasaponin I (SsaI), both in vitro and in xenograft models, alone or combined with bevacizumab. Angiogenic and EMT marker expression and focal adhesion kinase (FAK)/paxillin pathway activation were assessed.

Results

ST3Gal1 was amplified and overexpressed in EC and correlated with advanced stage, deep myometrial invasion, and poor prognosis. It directly glycosylated VEGF‐A and activated FAK/paxillin signaling, promoting VEGF‐A expression and EMT. ST3Gal1 inhibition via SsaI reduced VEGF‐A signaling, reversed EMT marker expression, and suppressed cell migration and invasion, particularly in RL95‐2 cells. In vivo, SsaI significantly inhibited tumor growth and angiogenesis, with the most pronounced effect observed in combination with bevacizumab. Dual treatment disrupted ST3Gal1–VEGF‐A interactions and downregulated angiogenic and EMT markers.

Conclusion

ST3Gal1 promotes EC progression by enhancing VEGF‐A signaling and EMT via the FAK/paxillin pathway. Its inhibition improves the efficacy of antiangiogenic therapy, supporting ST3Gal1 as a promising therapeutic target to overcome anti‐VEGF‐A resistance in advanced EC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SialyltransferasesEndometrial NeoplasmsVascular Endothelial Growth Factor AFemaleHumansAnimalsbeta-Galactoside alpha-2,3-SialyltransferaseEpithelial-Mesenchymal TransitionMiceDrug Resistance, NeoplasmCell Line, TumorAngiogenesis InhibitorsBevacizumabMiddle AgedSaponinsXenograft Model Antitumor Assays

Stichwörter der Autor:innen

ST3Gal1VEGF‐Aangiogenesisendometrial cancerepithelial–mesenchymal transition

Substanzen

Sialyltransferasesbeta-Galactoside alpha-2,3-SialyltransferaseVascular Endothelial Growth Factor AST3GAL1 protein, humanAngiogenesis InhibitorsBevacizumabSaponinsVEGFA protein, human

Autor:innen und Institutionen

  • Department of Obstetrics and Gynecology, Taipei Veterans General Hospital, Taipei, Taiwan.
  • Department of Obstetrics and Gynecology, National Yang Ming Chiao Tung University, Taipei, Taiwan.
  • Institute of Clinical Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.
  • Graduate Institute of Medical Sciences, College of Medicine, Taipei Medical University, Taipei, Taiwan.
  • Department of Pathology and Laboratory Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.
  • Genomic Research Center, Academia Sinica, Taipei, Taiwan.

ORCID-Profile: Chia-Hao Liu, Shie-Liang Hsieh, Peng-Hui Wang

Förderung

  • National Science and Technology Council
  • Taipei Veterans General Hospital
  • Female Cancer Foundation, Taipei, Taiwan
  • Female Cancer Foundation

Zitieren

APA

Liu, C. H., Yang, S. T., Chao, W. T., Lin, C. H., Lee, Y. C., Lai, C. R., Hsieh, S. L., Wang, L. W., & Wang, P. H. (2025). Targeting the ST3 beta‐galactoside alpha‐2,3‐sialyltransferase 1 ( ST3Gal1 ) as a potential therapeutic strategy to overcome anti‐ VEGF resistance in endometrial cancer. International Journal of Gynecology & Obstetrics, 171(3), 1343-1354. https://doi.org/10.1002/ijgo.70292

Vancouver

Liu CH, Yang ST, Chao WT, Lin CH, Lee YC, Lai CR, et al. Targeting the ST3 beta‐galactoside alpha‐2,3‐sialyltransferase 1 ( ST3Gal1 ) as a potential therapeutic strategy to overcome anti‐ VEGF resistance in endometrial cancer. International Journal of Gynecology & Obstetrics. 2025;171(3):1343-1354. doi:10.1002/ijgo.70292

BibTeX
@article{Liu2025,
  author = {Liu, Chia-Hao and Yang, Szu-Ting and Chao, Wei-Ting and Lin, Chen-Hao and Lee, Yu-Chieh and Lai, Chiung-Ru and Hsieh, Shie-Liang and Wang, Liang-Wei and Wang, Peng-Hui},
  title = {Targeting the ST3 beta‐galactoside alpha‐2,3‐sialyltransferase 1 ( ST3Gal1 ) as a potential therapeutic strategy to overcome anti‐ VEGF resistance in endometrial cancer},
  journal = {International Journal of Gynecology & Obstetrics},
  year = {2025},
  volume = {171},
  number = {3},
  pages = {1343--1354},
  doi = {10.1002/ijgo.70292}
}
Kostenlos starten →